Our client is a cutting-edge biotechnology company dedicated to developing groundbreaking therapeuties that target kidney diseases and other hard to treat conditions. Their mission is to make a profound impact on patients' lives by pioneering first-in-class antibodies and innovative treatments.
As a Senior/Principal Scientist in Biomarker Development, you will be a key player in their research efforts to develop therapies that combat Kidney Disease. You will leverage your extensive industry experience to lead translational research initiatives, biomarker development, and uncover critical insights that guide their therapeutic programs.
- Lead translational research projects to bridge the gap between preclinical and clinical development, translating scientific discoveries into potential therapeutic solutions.
- Apply your expertise in human biomarker discovery/development to design and conduct experiments, analyze data, and identify relevant biomarkers to guide therapeutic development.
- Execute specific components of the translational biomarker strategy, to support active clinical and preclinical programs approaching IND for FIH studies.
- Collaborate closely with cross-functional teams, including research, preclinical, and clinical teams, to ensure alignment and drive projects forward.
- Analyze complex data sets, generate reports, and present findings to internal stakeholders and external partners.
- PhD or MS in a relevant scientific field.
- 5+ years of postgrad experience in translational medicine, with a strong focus on Immunology; Nephrology experience is a nice to have.
- Strong analytical and problem-solving skills.
- Excellent communication and presentation abilities.
- Proven track record of collaborating effectively in multidisciplinary teams.
- Demonstrated ability to drive research projects from conception to execution.
Full job description and company details available upon application. This position is managed by Sam Long at Meet Recruitment. Email firstname.lastname@example.org to discuss the position further.